Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...

Columnist Dagmar Munn has a Santa wish list for her outings over the holidays: accessible restrooms and good cutlery among ...

Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...

Columnist Kristin Neva recognizes the distinction between being thankful "in" a bad situation rather than "for" a bad situation.

A grant from the ALS Association will fund an early-stage clinical trial to test Tiziana's foralumab nasal spray in 20 ALS ...

The world's largest ALS patient-derived stem cell and biodata repository is now available to researchers globally.

Ractigen's RAG-21, a treatment for ALS linked to mutations in the FUS gene, has been granted orphan drug designation in the U ...

The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...

Although she did everything possible to learn about ALS, columnist Juliet Taylor says the disease often left her feeling ...

A Phase 2 trial testing oral ROCK inhibitor Bravyl in people with ALS is now fully enrolled at its highest dosing group.

A newly awarded grant from the ALS Association will support Asha Therapeutics' work to advance ASHA-624 into a first-in-human ...

The EMA recommended that NUZ-001, formerly monepantel, be granted orphan medicinal product designation to treat ALS in Europe ...